ALDEYRA THERAPEUTICS INC (ALDX)

US01438T1060 - Common Stock

4.7  -0.07 (-1.47%)

After market: 4.7 0 (0%)

Fundamental Rating

2

Overall ALDX gets a fundamental rating of 2 out of 10. We evaluated ALDX against 572 industry peers in the Biotechnology industry. ALDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALDX does not seem to be growing, but still is valued expensively.



1

1. Profitability

1.1 Basic Checks

ALDX had negative earnings in the past year.
In the past year ALDX has reported a negative cash flow from operations.
In the past 5 years ALDX always reported negative net income.
ALDX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ALDX (-38.18%) is comparable to the rest of the industry.
ALDX has a better Return On Equity (-52.64%) than 64.78% of its industry peers.
Industry RankSector Rank
ROA -38.18%
ROE -52.64%
ROIC N/A
ROA(3y)-28.1%
ROA(5y)-41.98%
ROE(3y)-33.5%
ROE(5y)-58.02%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALDX has more shares outstanding
The number of shares outstanding for ALDX has been increased compared to 5 years ago.
Compared to 1 year ago, ALDX has a worse debt to assets ratio.

2.2 Solvency

ALDX has an Altman-Z score of -0.35. This is a bad value and indicates that ALDX is not financially healthy and even has some risk of bankruptcy.
ALDX's Altman-Z score of -0.35 is fine compared to the rest of the industry. ALDX outperforms 63.01% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that ALDX is not too dependend on debt financing.
ALDX has a worse Debt to Equity ratio (0.18) than 69.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ALDX has a Current Ratio of 6.80. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALDX (6.80) is better than 66.55% of its industry peers.
A Quick Ratio of 6.80 indicates that ALDX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.80, ALDX is doing good in the industry, outperforming 66.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.8
Quick Ratio 6.8

3

3. Growth

3.1 Past

ALDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.85%.
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALDX will show a very strong growth in Earnings Per Share. The EPS will grow by 33.74% on average per year.
Based on estimates for the next years, ALDX will show a very strong growth in Revenue. The Revenue will grow by 172.22% on average per year.
EPS Next Y-46.23%
EPS Next 2Y13.09%
EPS Next 3Y18.97%
EPS Next 5Y33.74%
Revenue Next Year-100%
Revenue Next 2Y686.34%
Revenue Next 3Y264.8%
Revenue Next 5Y172.22%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

ALDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDX's earnings are expected to grow with 18.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.09%
EPS Next 3Y18.97%

0

5. Dividend

5.1 Amount

No dividends for ALDX!.
Industry RankSector Rank
Dividend Yield N/A

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (1/14/2025, 8:22:59 PM)

After market: 4.7 0 (0%)

4.7

-0.07 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners44.82%
Inst Owner Change-0.64%
Ins Owners2.4%
Ins Owner Change-0.58%
Market Cap279.88M
Analysts88.57
Price Target10.49 (123.19%)
Short Float %7.87%
Short Ratio7.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-46.44%
Min EPS beat(2)-93.66%
Max EPS beat(2)0.77%
EPS beat(4)2
Avg EPS beat(4)-18.22%
Min EPS beat(4)-93.66%
Max EPS beat(4)44.08%
EPS beat(8)6
Avg EPS beat(8)7.82%
EPS beat(12)10
Avg EPS beat(12)9.39%
EPS beat(16)11
Avg EPS beat(16)6.43%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-198.85%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-36.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.29
P/tB 3.29
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS1.43
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.18%
ROE -52.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.1%
ROA(5y)-41.98%
ROE(3y)-33.5%
ROE(5y)-58.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.8
Quick Ratio 6.8
Altman-Z -0.35
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.85%
Cap/Depr(5y)4.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.57%
EPS Next Y-46.23%
EPS Next 2Y13.09%
EPS Next 3Y18.97%
EPS Next 5Y33.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y686.34%
Revenue Next 3Y264.8%
Revenue Next 5Y172.22%
EBIT growth 1Y1.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.51%
EBIT Next 3Y18.69%
EBIT Next 5YN/A
FCF growth 1Y46.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.19%
OCF growth 3YN/A
OCF growth 5YN/A